Welcome to ULS!
Welcome to ULS!
> Products > Inhibitors & Agonists > JAK/STAT Signaling > EGFR
Products
EGFR

Chemical structure

Cat.No.

Product Name

CAS no.

Target

  • YN340185 Osimertinib 1421373-65-0

    Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respective...

  • YN340186 Osimertinib mesylate 1421373-66-1

    Osimertinib mesylate is the mesylate form of osimertinib, which is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug.

  • YN340253 AZ-5104 1421373-98-9

    AZ5104, the demethylated metabolite of AZD-9291, is a potent EGFR inhibitor with IC50 of <1 nM, 6 nM, 1 nM, and 25 nM for EGFR (L858R/T790M), EGFR (L858R), EGFR (L861Q), and EGFR (wildtype), respective...

  • YN340099 RTC-5 1423077-49-9

    RTC-5 (TRC-382) is an optimized phenothiazine with anti-cancer potency. RTC-5 demonstrates efficacy against a xenograft model of anEGFRdriven cancer, its effects is attributed to concomitant negative regulation of PI3K-AKT...

  • YN340228 PF-06459988 1428774-45-1

    PF-06459988 is an irreversible inhibitor of T790M-Containing EGFR Mutants.

  • YN340213 Lifirafenib 1446090-79-4

    Lifirafenib (BGB-283) is a novel and potentRafKinase and EGFRinhibitor with IC50 values of 23 and 29nM for recombinant BRafV600E and EGFR, respectively.

  • YN340181 Rociletinib hydrobromide 1446700-26-0

    Rociletinib hydrobromide (CO-1686 hydrobromide) is an orally delivered kinase inhibitor that specifically targets the mutant forms ofEGFRincluding T790M, and theKivalues for EGFRL858R/T790M and EGFRWT are 21.5nM...

  • YN340224 Naquotinib mesylate 1448237-05-5

    Naquotinib mesylate (ASP8273 mesylate) is an orally available, mutant-selective and irreversibleEGFRinhibitor; with IC50s of 8-33nM toward EGFR mutants and 230nM for EGFR.

  • YN340115 Nazartinib 1508250-71-2

    Nazartinib (EGF816, NVS-816) is a covalent, irreversible, mutant-selective EGFR inhibitor that has nanomolar inhibitory potency against activating mt (L858R, ex19del) and T790M mt, with up to 60-fold selectivity over wild typ...

  • YN340226 Avitinib maleate 1557268-88-8

    Avitinib maleate is a pyrrolopyrimidine-based irreversible epidermal growth factor receptor (EGFR) inhibitor with an IC50 of 7.68nM.

  • YN340016 TX1-85-1 1603845-32-4

    TX1-85-1 is an irreversible Her3 (ErbB3)inhibitor with an IC50 of 23nM. TX1-85-1 is also the first selective Her3 lig and , which forms a covalent bond with Cys721 located in the ATP-binding site of Her3. TX1-85-1 induces ...

  • YN340212 Zorifertinib 1626387-80-1

    AZD3759 is a potent, oral active, CNS-penetrant EGFR inhibitor with IC50 of 0.3 nM, 0.2 nM, and 0.2 nM for EGFR (WT), EGFR (L858R), and EGFR (exon 19Del), respectively. Phase 1.

  • YN340200 Tarloxotinib bromide 1636180-98-7

    Tarloxotinib bromide (TH-4000) is an irreversibleEGFR/HER2inhibitor.

  • YN340210 FIIN-3 1637735-84-2

    FIIN-3 is an irreversible inhibitor ofFGFRwith an IC50 of 13.1, 21, 31.4, and 35.3nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.

  • YN340225 EGFR-IN-3 1660963-42-7

    EGFR-IN-3 is an epidermal growth factor receptor(EGFR)inhibitor.

  • YN340076 TAS6417 1661854-97-2

    TAS6417 is a novel EGFR inhibitor that targets EGFR exon 20 insertion mutations while sparing wild-type (WT) EGFR. IC50 values ranges from 1.1 ± 0.1 to 8.0 ± 1.1 nmol/L.

  • YN340119 Mavelertinib 1776112-90-3

    Mavelertinib is a selective, orally available and irreversibleEGFR tyrosine kinase inhibitor (EGFR TKI), with IC50s of 5, 4, 12 and 3nM for Del, L858R, and double mutants T790M/L858R and T790M/Del, respectiv...

  • YN340140 Mobocertinib 1847461-43-1

    Mobocertinib (TAK788), an investigational TKI, is a potent, selective preclinical inhibitor of epidermal growth factor receptor (EGFR) and HER2 mutations. Mobocertinib (TAK788) is an antineoplastic agent.

  • YN340081 Almonertinib 1899921-05-1

    HS-10296 is a small molecule inhibitor of EGFR-activating mutations and T790M-resistant mutation with limited activity against wild-type EGFR.

  • YN340066 Lazertinib 1903008-80-9

    Lazertinib (YH25448,GNS-1480) is a potent, highly mutant-selective and irreversible EGFR-TKI with IC50 values of 1.7 nM, 2 nM, 5 nM, 20.6 nM and 76 nM for Del19/T790M, L858R/T790M, Del19, L85R and Wild type E...

    Contact

    TELL : +86-020-82000279

    Email: sales@ubiochem.com

    Add:Room 519, Block F, Guangzhou International Business Incubator, No.3 Lanyue Road, Science Town, Huangpu District, Guangzhou, China.

ULS products are chemical reagents for Research Use Only!Copyright © 2020-2021 ULS. All Rights Reserved.备案号:粤ICP备2021013238号-2
0.545775s